Across 4 studies, all reported beneficial effects of turmeric/curcumin on reducing inflammatory markers, with 3 reaching statistical significance. The predominant effect size was small, though one systematic review reported a moderate effect. Evidence comes primarily from systematic reviews and general reviews, but study durations and doses were not consistently reported.
Caveats: Available evidence is overwhelmingly positive — clinical literature in this area is subject to publication bias (null-result studies are less likely to be published or indexed). Evidence base is small (only 4 studies) — conclusions should be considered preliminary. Doses and study durations were not reported in the available studies, making it difficult to determine effective dosing or duration windows.
The available evidence suggests that curcumin is a safe medicinal agent that improves multiple clinical outcomes
from: Curcumin and multiple health outcomes: critical umbrella review of intervention meta-analyThe findings suggest that curcumin has potentially positive effects on ... inflammatory markers and oxidative stress
It also appears to have the capability to lower biomarkers associated with inflammation
Curcumin's anti-inflammatory properties are related to the inhibition of the NF-κB pathway, leading to the reduction in inflammatory markers in adipocytes and macrophages
curcumin reduces inflammatory markers (IL-8, TNF-α) in endometriosis